nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—Erlotinib—lung cancer	0.333	1	CrCtD
Gefitinib—Vandetanib—Erlotinib—lung cancer	0.162	1	CrCrCtD
Gefitinib—ERBB3—lung cancer	0.0758	0.433	CbGaD
Gefitinib—EGFR—lung cancer	0.034	0.194	CbGaD
Gefitinib—ABCG2—lung cancer	0.0248	0.142	CbGaD
Gefitinib—MKNK1—Erlotinib—lung cancer	0.0221	0.101	CbGbCtD
Gefitinib—CYP1A1—lung cancer	0.0194	0.111	CbGaD
Gefitinib—IRAK1—Crizotinib—lung cancer	0.0166	0.0756	CbGbCtD
Gefitinib—EPHA6—Crizotinib—lung cancer	0.0146	0.0669	CbGbCtD
Gefitinib—EPHA6—Erlotinib—lung cancer	0.0141	0.0645	CbGbCtD
Gefitinib—HIPK4—Erlotinib—lung cancer	0.0141	0.0645	CbGbCtD
Gefitinib—STK10—Crizotinib—lung cancer	0.0132	0.0601	CbGbCtD
Gefitinib—STK10—Erlotinib—lung cancer	0.0127	0.058	CbGbCtD
Gefitinib—EGFR—Erlotinib—lung cancer	0.0127	0.058	CbGbCtD
Gefitinib—MAP2K5—Erlotinib—lung cancer	0.0116	0.0528	CbGbCtD
Gefitinib—MAP3K19—Crizotinib—lung cancer	0.011	0.0503	CbGbCtD
Gefitinib—ALB—lung cancer	0.0108	0.0618	CbGaD
Gefitinib—MAP3K19—Erlotinib—lung cancer	0.0106	0.0485	CbGbCtD
Gefitinib—ABCB1—lung cancer	0.0103	0.059	CbGaD
Gefitinib—EGFR—Docetaxel—lung cancer	0.0084	0.0384	CbGbCtD
Gefitinib—ABCG2—Topotecan—lung cancer	0.00388	0.0177	CbGbCtD
Gefitinib—ABCG2—Teniposide—lung cancer	0.00344	0.0157	CbGbCtD
Gefitinib—ORM1—Erlotinib—lung cancer	0.00343	0.0157	CbGbCtD
Gefitinib—ABCG2—Erlotinib—lung cancer	0.0021	0.00957	CbGbCtD
Gefitinib—CYP1A1—Erlotinib—lung cancer	0.00193	0.00884	CbGbCtD
Gefitinib—ABCG2—Paclitaxel—lung cancer	0.00192	0.00876	CbGbCtD
Gefitinib—CYP3A5—Teniposide—lung cancer	0.0019	0.0087	CbGbCtD
Gefitinib—ABCG2—Irinotecan—lung cancer	0.00189	0.00864	CbGbCtD
Gefitinib—ABCG2—Cisplatin—lung cancer	0.00154	0.00705	CbGbCtD
Gefitinib—CYP2C19—Teniposide—lung cancer	0.00154	0.00702	CbGbCtD
Gefitinib—ABCG2—Etoposide—lung cancer	0.00152	0.00692	CbGbCtD
Gefitinib—ALB—Erlotinib—lung cancer	0.00145	0.0066	CbGbCtD
Gefitinib—ABCB1—Topotecan—lung cancer	0.0014	0.00638	CbGbCtD
Gefitinib—ABCG2—Docetaxel—lung cancer	0.00139	0.00634	CbGbCtD
Gefitinib—ALB—Irinotecan—lung cancer	0.0013	0.00596	CbGbCtD
Gefitinib—CYP2C9—Teniposide—lung cancer	0.00128	0.00583	CbGbCtD
Gefitinib—CYP3A5—Crizotinib—lung cancer	0.0012	0.0055	CbGbCtD
Gefitinib—CYP3A5—Erlotinib—lung cancer	0.00116	0.0053	CbGbCtD
Gefitinib—CYP3A5—Paclitaxel—lung cancer	0.00106	0.00485	CbGbCtD
Gefitinib—CYP3A5—Irinotecan—lung cancer	0.00105	0.00479	CbGbCtD
Gefitinib—ABCG2—Doxorubicin—lung cancer	0.00103	0.00472	CbGbCtD
Gefitinib—ABCG2—Methotrexate—lung cancer	0.001	0.00457	CbGbCtD
Gefitinib—ABCB1—Vinorelbine—lung cancer	0.000985	0.0045	CbGbCtD
Gefitinib—CYP2D6—Vinorelbine—lung cancer	0.000928	0.00424	CbGbCtD
Gefitinib—CYP3A5—Etoposide—lung cancer	0.00084	0.00384	CbGbCtD
Gefitinib—CYP3A4—Topotecan—lung cancer	0.000837	0.00382	CbGbCtD
Gefitinib—ABCB1—Crizotinib—lung cancer	0.000784	0.00358	CbGbCtD
Gefitinib—CYP3A5—Docetaxel—lung cancer	0.000769	0.00351	CbGbCtD
Gefitinib—ABCB1—Gemcitabine—lung cancer	0.000766	0.0035	CbGbCtD
Gefitinib—ABCB1—Erlotinib—lung cancer	0.000756	0.00345	CbGbCtD
Gefitinib—CYP3A4—Teniposide—lung cancer	0.000743	0.00339	CbGbCtD
Gefitinib—CYP2C9—Paclitaxel—lung cancer	0.000713	0.00326	CbGbCtD
Gefitinib—CYP2D6—Erlotinib—lung cancer	0.000712	0.00325	CbGbCtD
Gefitinib—ABCB1—Paclitaxel—lung cancer	0.000692	0.00316	CbGbCtD
Gefitinib—ALB—Methotrexate—lung cancer	0.000691	0.00315	CbGbCtD
Gefitinib—ABCB1—Irinotecan—lung cancer	0.000683	0.00312	CbGbCtD
Gefitinib—ABCB1—Vinblastine—lung cancer	0.000607	0.00277	CbGbCtD
Gefitinib—EGFR—mammary gland—lung cancer	0.000606	0.0366	CbGeAlD
Gefitinib—CYP3A4—Vinorelbine—lung cancer	0.00059	0.00269	CbGbCtD
Gefitinib—CSNK1E—mammary gland—lung cancer	0.000583	0.0351	CbGeAlD
Gefitinib—CYP2C9—Cisplatin—lung cancer	0.000573	0.00262	CbGbCtD
Gefitinib—CYP2D6—Vinblastine—lung cancer	0.000572	0.00261	CbGbCtD
Gefitinib—ERBB3—mammary gland—lung cancer	0.000562	0.0339	CbGeAlD
Gefitinib—ABCB1—Cisplatin—lung cancer	0.000556	0.00254	CbGbCtD
Gefitinib—ABCB1—Etoposide—lung cancer	0.000547	0.0025	CbGbCtD
Gefitinib—MKNK2—mammary gland—lung cancer	0.000535	0.0323	CbGeAlD
Gefitinib—MKNK1—mammary gland—lung cancer	0.000528	0.0318	CbGeAlD
Gefitinib—ABCB1—Docetaxel—lung cancer	0.0005	0.00228	CbGbCtD
Gefitinib—MAP3K19—respiratory system—lung cancer	0.000499	0.0301	CbGeAlD
Gefitinib—CYP3A4—Crizotinib—lung cancer	0.000469	0.00214	CbGbCtD
Gefitinib—CYP3A4—Erlotinib—lung cancer	0.000453	0.00207	CbGbCtD
Gefitinib—CYP3A4—Paclitaxel—lung cancer	0.000415	0.00189	CbGbCtD
Gefitinib—CYP3A4—Irinotecan—lung cancer	0.000409	0.00187	CbGbCtD
Gefitinib—CSNK1E—respiratory system—lung cancer	0.000388	0.0234	CbGeAlD
Gefitinib—ERBB3—respiratory system—lung cancer	0.000375	0.0226	CbGeAlD
Gefitinib—ABCB1—Doxorubicin—lung cancer	0.000373	0.0017	CbGbCtD
Gefitinib—CYP3A4—Vinblastine—lung cancer	0.000364	0.00166	CbGbCtD
Gefitinib—ABCB1—Methotrexate—lung cancer	0.000361	0.00165	CbGbCtD
Gefitinib—CHEK2—bone marrow—lung cancer	0.000359	0.0217	CbGeAlD
Gefitinib—MKNK2—respiratory system—lung cancer	0.000356	0.0215	CbGeAlD
Gefitinib—CYP2D6—Doxorubicin—lung cancer	0.000351	0.0016	CbGbCtD
Gefitinib—CYP3A4—Etoposide—lung cancer	0.000328	0.0015	CbGbCtD
Gefitinib—CHEK2—lung—lung cancer	0.000325	0.0196	CbGeAlD
Gefitinib—CSNK1E—bronchus—lung cancer	0.00032	0.0193	CbGeAlD
Gefitinib—IRAK4—bronchus—lung cancer	0.000315	0.019	CbGeAlD
Gefitinib—ERBB3—epithelium—lung cancer	0.000313	0.0189	CbGeAlD
Gefitinib—CYP3A4—Docetaxel—lung cancer	0.0003	0.00137	CbGbCtD
Gefitinib—MKNK2—epithelium—lung cancer	0.000298	0.018	CbGeAlD
Gefitinib—MKNK2—bronchus—lung cancer	0.000293	0.0177	CbGeAlD
Gefitinib—IRAK1—bronchus—lung cancer	0.000293	0.0177	CbGeAlD
Gefitinib—STK10—respiratory system—lung cancer	0.00029	0.0175	CbGeAlD
Gefitinib—MKNK1—bronchus—lung cancer	0.00029	0.0175	CbGeAlD
Gefitinib—CSNK1E—trachea—lung cancer	0.000287	0.0173	CbGeAlD
Gefitinib—IRAK4—trachea—lung cancer	0.000282	0.017	CbGeAlD
Gefitinib—ERBB3—trachea—lung cancer	0.000277	0.0167	CbGeAlD
Gefitinib—ALB—mammary gland—lung cancer	0.000276	0.0167	CbGeAlD
Gefitinib—MAP3K19—lung—lung cancer	0.000265	0.016	CbGeAlD
Gefitinib—MKNK2—trachea—lung cancer	0.000263	0.0159	CbGeAlD
Gefitinib—SBK1—lymph node—lung cancer	0.000255	0.0154	CbGeAlD
Gefitinib—MKNK2—cardiac atrium—lung cancer	0.000247	0.0149	CbGeAlD
Gefitinib—MKNK1—cardiac atrium—lung cancer	0.000244	0.0147	CbGeAlD
Gefitinib—STK10—bronchus—lung cancer	0.000238	0.0144	CbGeAlD
Gefitinib—IRAK4—bone marrow—lung cancer	0.000224	0.0135	CbGeAlD
Gefitinib—CYP3A4—Doxorubicin—lung cancer	0.000223	0.00102	CbGbCtD
Gefitinib—CHEK2—lymph node—lung cancer	0.000222	0.0134	CbGeAlD
Gefitinib—Lapatinib—ERBB2—lung cancer	0.00022	0.102	CrCbGaD
Gefitinib—EGFR—lung—lung cancer	0.000214	0.0129	CbGeAlD
Gefitinib—MAP2K5—bronchus—lung cancer	0.000213	0.0128	CbGeAlD
Gefitinib—MKNK2—bone marrow—lung cancer	0.000209	0.0126	CbGeAlD
Gefitinib—IRAK1—bone marrow—lung cancer	0.000209	0.0126	CbGeAlD
Gefitinib—CSNK1E—lung—lung cancer	0.000206	0.0124	CbGeAlD
Gefitinib—MKNK1—bone marrow—lung cancer	0.000206	0.0124	CbGeAlD
Gefitinib—IRAK4—lung—lung cancer	0.000203	0.0122	CbGeAlD
Gefitinib—ERBB3—lung—lung cancer	0.000199	0.012	CbGeAlD
Gefitinib—MAP2K5—trachea—lung cancer	0.000191	0.0115	CbGeAlD
Gefitinib—MKNK2—lung—lung cancer	0.000189	0.0114	CbGeAlD
Gefitinib—IRAK1—lung—lung cancer	0.000189	0.0114	CbGeAlD
Gefitinib—MKNK1—lung—lung cancer	0.000187	0.0113	CbGeAlD
Gefitinib—MAP2K5—cardiac atrium—lung cancer	0.00018	0.0108	CbGeAlD
Gefitinib—CHEK2—Docetaxel—Paclitaxel—lung cancer	0.000173	0.145	CbGdCrCtD
Gefitinib—CYP2C9—mammary gland—lung cancer	0.000173	0.0104	CbGeAlD
Gefitinib—STK10—bone marrow—lung cancer	0.00017	0.0102	CbGeAlD
Gefitinib—Afatinib—ERBB2—lung cancer	0.000156	0.0724	CrCbGaD
Gefitinib—STK10—lung—lung cancer	0.000154	0.00928	CbGeAlD
Gefitinib—EGFR—lymph node—lung cancer	0.000147	0.00885	CbGeAlD
Gefitinib—CSNK1E—lymph node—lung cancer	0.000141	0.00851	CbGeAlD
Gefitinib—IRAK4—lymph node—lung cancer	0.000139	0.00837	CbGeAlD
Gefitinib—ERBB3—Podofilox—Teniposide—lung cancer	0.000138	0.116	CbGdCrCtD
Gefitinib—MAP2K5—lung—lung cancer	0.000137	0.00829	CbGeAlD
Gefitinib—ERBB3—lymph node—lung cancer	0.000136	0.00821	CbGeAlD
Gefitinib—Bosutinib—TXK—lung cancer	0.000133	0.0616	CrCbGaD
Gefitinib—MKNK2—lymph node—lung cancer	0.000129	0.00781	CbGeAlD
Gefitinib—IRAK1—lymph node—lung cancer	0.000129	0.00781	CbGeAlD
Gefitinib—MKNK1—lymph node—lung cancer	0.000128	0.00771	CbGeAlD
Gefitinib—Vandetanib—AXL—lung cancer	0.000126	0.0587	CrCbGaD
Gefitinib—ORM1—bone marrow—lung cancer	0.000123	0.00743	CbGeAlD
Gefitinib—CYP1A1—respiratory system—lung cancer	0.000119	0.00721	CbGeAlD
Gefitinib—Bosutinib—AXL—lung cancer	0.000118	0.0549	CrCbGaD
Gefitinib—CYP3A5—respiratory system—lung cancer	0.000117	0.00705	CbGeAlD
Gefitinib—ORM1—lung—lung cancer	0.000112	0.00673	CbGeAlD
Gefitinib—CHEK2—Vindesine—Vinorelbine—lung cancer	0.00011	0.0925	CbGdCrCtD
Gefitinib—Vandetanib—FGR—lung cancer	0.000108	0.0499	CrCbGaD
Gefitinib—STK10—lymph node—lung cancer	0.000105	0.00635	CbGeAlD
Gefitinib—Lapatinib—EGFR—lung cancer	0.000104	0.0483	CrCbGaD
Gefitinib—Bosutinib—FGR—lung cancer	0.000101	0.0467	CrCbGaD
Gefitinib—Bosutinib—MAP2K1—lung cancer	0.000101	0.0467	CrCbGaD
Gefitinib—CYP1A1—epithelium—lung cancer	9.99e-05	0.00602	CbGeAlD
Gefitinib—CYP1A1—bronchus—lung cancer	9.83e-05	0.00593	CbGeAlD
Gefitinib—MAP2K5—lymph node—lung cancer	9.4e-05	0.00567	CbGeAlD
Gefitinib—CHEK2—Podofilox—Teniposide—lung cancer	9.31e-05	0.0784	CbGdCrCtD
Gefitinib—CYP1A1—trachea—lung cancer	8.83e-05	0.00533	CbGeAlD
Gefitinib—CHEK2—Vindesine—Vinblastine—lung cancer	8.78e-05	0.074	CbGdCrCtD
Gefitinib—CHEK2—Paclitaxel—Docetaxel—lung cancer	8.62e-05	0.0726	CbGdCrCtD
Gefitinib—CYP1A1—cardiac atrium—lung cancer	8.29e-05	0.005	CbGeAlD
Gefitinib—ERBB3—Podofilox—Etoposide—lung cancer	8.2e-05	0.069	CbGdCrCtD
Gefitinib—Vandetanib—ERBB3—lung cancer	7.66e-05	0.0355	CrCbGaD
Gefitinib—ORM1—lymph node—lung cancer	7.63e-05	0.0046	CbGeAlD
Gefitinib—Afatinib—EGFR—lung cancer	7.38e-05	0.0343	CrCbGaD
Gefitinib—ABCG2—bone marrow—lung cancer	7.38e-05	0.00445	CbGeAlD
Gefitinib—Bosutinib—ALK—lung cancer	7.17e-05	0.0333	CrCbGaD
Gefitinib—Bosutinib—ERBB3—lung cancer	7.17e-05	0.0333	CrCbGaD
Gefitinib—ERBB3—Vinblastine—Vinorelbine—lung cancer	7.06e-05	0.0594	CbGdCrCtD
Gefitinib—Erlotinib—UGT1A1—lung cancer	6.78e-05	0.0314	CrCbGaD
Gefitinib—ALB—lymph node—lung cancer	6.69e-05	0.00403	CbGeAlD
Gefitinib—ABCG2—lung—lung cancer	6.68e-05	0.00403	CbGeAlD
Gefitinib—CYP1A1—lung—lung cancer	6.34e-05	0.00383	CbGeAlD
Gefitinib—ABCB1—respiratory system—lung cancer	6.21e-05	0.00374	CbGeAlD
Gefitinib—CYP3A5—lung—lung cancer	6.2e-05	0.00374	CbGeAlD
Gefitinib—CHEK2—Vincristine—Vinorelbine—lung cancer	5.93e-05	0.0499	CbGdCrCtD
Gefitinib—CHEK2—Vinorelbine—Vinblastine—lung cancer	5.54e-05	0.0467	CbGdCrCtD
Gefitinib—CHEK2—Teniposide—Etoposide—lung cancer	5.54e-05	0.0466	CbGdCrCtD
Gefitinib—CHEK2—Podofilox—Etoposide—lung cancer	5.54e-05	0.0466	CbGdCrCtD
Gefitinib—Afatinib—ABCG2—lung cancer	5.39e-05	0.025	CrCbGaD
Gefitinib—Erlotinib—EGFR—lung cancer	5.21e-05	0.0242	CrCbGaD
Gefitinib—ABCB1—epithelium—lung cancer	5.19e-05	0.00313	CbGeAlD
Gefitinib—Vandetanib—SRC—lung cancer	5.11e-05	0.0237	CrCbGaD
Gefitinib—Vandetanib—KDR—lung cancer	4.8e-05	0.0223	CrCbGaD
Gefitinib—Bosutinib—SRC—lung cancer	4.78e-05	0.0222	CrCbGaD
Gefitinib—CHEK2—Vinblastine—Vinorelbine—lung cancer	4.77e-05	0.0401	CbGdCrCtD
Gefitinib—CHEK2—Vincristine—Vinblastine—lung cancer	4.74e-05	0.0399	CbGdCrCtD
Gefitinib—ABCB1—trachea—lung cancer	4.59e-05	0.00277	CbGeAlD
Gefitinib—ABCG2—lymph node—lung cancer	4.57e-05	0.00276	CbGeAlD
Gefitinib—CYP1A1—lymph node—lung cancer	4.34e-05	0.00262	CbGeAlD
Gefitinib—Vandetanib—VEGFA—lung cancer	4.07e-05	0.0189	CrCbGaD
Gefitinib—Cisapride—CYP2A6—lung cancer	4.01e-05	0.0186	CrCbGaD
Gefitinib—Erlotinib—ABCG2—lung cancer	3.81e-05	0.0177	CrCbGaD
Gefitinib—ABCB1—bone marrow—lung cancer	3.64e-05	0.00219	CbGeAlD
Gefitinib—Vandetanib—EGFR—lung cancer	3.44e-05	0.0159	CrCbGaD
Gefitinib—ABCB1—lung—lung cancer	3.3e-05	0.00199	CbGeAlD
Gefitinib—Bosutinib—EGFR—lung cancer	3.21e-05	0.0149	CrCbGaD
Gefitinib—Lapatinib—ABCB1—lung cancer	3.17e-05	0.0147	CrCbGaD
Gefitinib—Erlotinib—CYP1A1—lung cancer	2.98e-05	0.0138	CrCbGaD
Gefitinib—CHEK2—Epirubicin—Doxorubicin—lung cancer	2.67e-05	0.0225	CbGdCrCtD
Gefitinib—Iloperidone—CYP2E1—lung cancer	2.63e-05	0.0122	CrCbGaD
Gefitinib—Dermatitis—Erlotinib—lung cancer	2.55e-05	0.000542	CcSEcCtD
Gefitinib—Angiopathy—Docetaxel—lung cancer	2.55e-05	0.000542	CcSEcCtD
Gefitinib—Skin disorder—Cisplatin—lung cancer	2.55e-05	0.000541	CcSEcCtD
Gefitinib—Mediastinal disorder—Docetaxel—lung cancer	2.53e-05	0.000538	CcSEcCtD
Gefitinib—Cough—Paclitaxel—lung cancer	2.52e-05	0.000535	CcSEcCtD
Gefitinib—Asthenia—Vinorelbine—lung cancer	2.51e-05	0.000534	CcSEcCtD
Gefitinib—Vandetanib—ABCG2—lung cancer	2.51e-05	0.0116	CrCbGaD
Gefitinib—Decreased appetite—Irinotecan—lung cancer	2.51e-05	0.000534	CcSEcCtD
Gefitinib—Arrhythmia—Docetaxel—lung cancer	2.51e-05	0.000533	CcSEcCtD
Gefitinib—Dyspnoea—Gemcitabine—lung cancer	2.51e-05	0.000533	CcSEcCtD
Gefitinib—Nausea—Vinblastine—lung cancer	2.5e-05	0.000532	CcSEcCtD
Gefitinib—Anorexia—Cisplatin—lung cancer	2.5e-05	0.000531	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Irinotecan—lung cancer	2.49e-05	0.00053	CcSEcCtD
Gefitinib—Fatigue—Irinotecan—lung cancer	2.49e-05	0.000529	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	2.49e-05	0.000529	CcSEcCtD
Gefitinib—Alopecia—Docetaxel—lung cancer	2.48e-05	0.000528	CcSEcCtD
Gefitinib—Pancreatitis—Methotrexate—lung cancer	2.48e-05	0.000527	CcSEcCtD
Gefitinib—Pruritus—Vinorelbine—lung cancer	2.48e-05	0.000527	CcSEcCtD
Gefitinib—Pain—Irinotecan—lung cancer	2.47e-05	0.000525	CcSEcCtD
Gefitinib—Constipation—Irinotecan—lung cancer	2.47e-05	0.000525	CcSEcCtD
Gefitinib—Hypotension—Cisplatin—lung cancer	2.45e-05	0.000521	CcSEcCtD
Gefitinib—Malnutrition—Docetaxel—lung cancer	2.44e-05	0.00052	CcSEcCtD
Gefitinib—Decreased appetite—Gemcitabine—lung cancer	2.44e-05	0.00052	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	2.44e-05	0.000519	CcSEcCtD
Gefitinib—Nausea—Topotecan—lung cancer	2.43e-05	0.000517	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Gemcitabine—lung cancer	2.43e-05	0.000516	CcSEcCtD
Gefitinib—Fatigue—Gemcitabine—lung cancer	2.42e-05	0.000515	CcSEcCtD
Gefitinib—Constipation—Gemcitabine—lung cancer	2.4e-05	0.000511	CcSEcCtD
Gefitinib—Pain—Gemcitabine—lung cancer	2.4e-05	0.000511	CcSEcCtD
Gefitinib—Nausea—Erlotinib—lung cancer	2.4e-05	0.000511	CcSEcCtD
Gefitinib—Dry mouth—Paclitaxel—lung cancer	2.4e-05	0.000511	CcSEcCtD
Gefitinib—Diarrhoea—Vinorelbine—lung cancer	2.39e-05	0.000509	CcSEcCtD
Gefitinib—Infection—Etoposide—lung cancer	2.38e-05	0.000507	CcSEcCtD
Gefitinib—Gastrointestinal pain—Irinotecan—lung cancer	2.36e-05	0.000502	CcSEcCtD
Gefitinib—Dehydration—Doxorubicin—lung cancer	2.36e-05	0.000501	CcSEcCtD
Gefitinib—Thrombocytopenia—Etoposide—lung cancer	2.35e-05	0.0005	CcSEcCtD
Gefitinib—Infection—Paclitaxel—lung cancer	2.34e-05	0.000497	CcSEcCtD
Gefitinib—Dyspnoea—Cisplatin—lung cancer	2.34e-05	0.000497	CcSEcCtD
Gefitinib—Skin disorder—Etoposide—lung cancer	2.33e-05	0.000496	CcSEcCtD
Gefitinib—Dry skin—Doxorubicin—lung cancer	2.32e-05	0.000494	CcSEcCtD
Gefitinib—Shock—Paclitaxel—lung cancer	2.32e-05	0.000492	CcSEcCtD
Gefitinib—Nervous system disorder—Paclitaxel—lung cancer	2.31e-05	0.000491	CcSEcCtD
Gefitinib—Hypokalaemia—Doxorubicin—lung cancer	2.31e-05	0.00049	CcSEcCtD
Gefitinib—Thrombocytopenia—Paclitaxel—lung cancer	2.3e-05	0.00049	CcSEcCtD
Gefitinib—Anorexia—Etoposide—lung cancer	2.29e-05	0.000487	CcSEcCtD
Gefitinib—Skin disorder—Paclitaxel—lung cancer	2.29e-05	0.000486	CcSEcCtD
Gefitinib—Abdominal pain—Irinotecan—lung cancer	2.28e-05	0.000485	CcSEcCtD
Gefitinib—Body temperature increased—Irinotecan—lung cancer	2.28e-05	0.000485	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Doxorubicin—lung cancer	2.28e-05	0.000485	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Doxorubicin—lung cancer	2.28e-05	0.000485	CcSEcCtD
Gefitinib—Decreased appetite—Cisplatin—lung cancer	2.28e-05	0.000484	CcSEcCtD
Gefitinib—Pneumonia—Methotrexate—lung cancer	2.27e-05	0.000482	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Cisplatin—lung cancer	2.26e-05	0.000481	CcSEcCtD
Gefitinib—Anaemia—Docetaxel—lung cancer	2.26e-05	0.00048	CcSEcCtD
Gefitinib—Infestation NOS—Methotrexate—lung cancer	2.25e-05	0.000479	CcSEcCtD
Gefitinib—Infestation—Methotrexate—lung cancer	2.25e-05	0.000479	CcSEcCtD
Gefitinib—ABCB1—lymph node—lung cancer	2.25e-05	0.00136	CbGeAlD
Gefitinib—Afatinib—ABCB1—lung cancer	2.24e-05	0.0104	CrCbGaD
Gefitinib—Anorexia—Paclitaxel—lung cancer	2.24e-05	0.000477	CcSEcCtD
Gefitinib—Hypotension—Etoposide—lung cancer	2.24e-05	0.000477	CcSEcCtD
Gefitinib—Pain—Cisplatin—lung cancer	2.24e-05	0.000477	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Methotrexate—lung cancer	2.24e-05	0.000475	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Doxorubicin—lung cancer	2.23e-05	0.000475	CcSEcCtD
Gefitinib—Vomiting—Vinorelbine—lung cancer	2.22e-05	0.000473	CcSEcCtD
Gefitinib—Body temperature increased—Gemcitabine—lung cancer	2.22e-05	0.000473	CcSEcCtD
Gefitinib—Rash—Vinorelbine—lung cancer	2.21e-05	0.000469	CcSEcCtD
Gefitinib—Dermatitis—Vinorelbine—lung cancer	2.2e-05	0.000469	CcSEcCtD
Gefitinib—Hypotension—Paclitaxel—lung cancer	2.2e-05	0.000468	CcSEcCtD
Gefitinib—Stomatitis—Methotrexate—lung cancer	2.2e-05	0.000467	CcSEcCtD
Gefitinib—Conjunctivitis—Methotrexate—lung cancer	2.19e-05	0.000466	CcSEcCtD
Gefitinib—Haematuria—Methotrexate—lung cancer	2.15e-05	0.000457	CcSEcCtD
Gefitinib—Pancreatitis—Doxorubicin—lung cancer	2.15e-05	0.000457	CcSEcCtD
Gefitinib—Dyspnoea—Etoposide—lung cancer	2.14e-05	0.000455	CcSEcCtD
Gefitinib—Cough—Docetaxel—lung cancer	2.13e-05	0.000454	CcSEcCtD
Gefitinib—Hepatobiliary disease—Methotrexate—lung cancer	2.13e-05	0.000453	CcSEcCtD
Gefitinib—Epistaxis—Methotrexate—lung cancer	2.13e-05	0.000452	CcSEcCtD
Gefitinib—Hypersensitivity—Irinotecan—lung cancer	2.13e-05	0.000452	CcSEcCtD
Gefitinib—Dyspnoea—Paclitaxel—lung cancer	2.1e-05	0.000446	CcSEcCtD
Gefitinib—Decreased appetite—Etoposide—lung cancer	2.09e-05	0.000444	CcSEcCtD
Gefitinib—Nausea—Vinorelbine—lung cancer	2.08e-05	0.000442	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Etoposide—lung cancer	2.07e-05	0.000441	CcSEcCtD
Gefitinib—Body temperature increased—Cisplatin—lung cancer	2.07e-05	0.000441	CcSEcCtD
Gefitinib—Asthenia—Irinotecan—lung cancer	2.07e-05	0.00044	CcSEcCtD
Gefitinib—Fatigue—Etoposide—lung cancer	2.07e-05	0.00044	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	2.07e-05	0.00044	CcSEcCtD
Gefitinib—Constipation—Etoposide—lung cancer	2.05e-05	0.000437	CcSEcCtD
Gefitinib—Pain—Etoposide—lung cancer	2.05e-05	0.000437	CcSEcCtD
Gefitinib—Decreased appetite—Paclitaxel—lung cancer	2.05e-05	0.000435	CcSEcCtD
Gefitinib—Dry mouth—Docetaxel—lung cancer	2.04e-05	0.000433	CcSEcCtD
Gefitinib—Haemoglobin—Methotrexate—lung cancer	2.03e-05	0.000433	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Paclitaxel—lung cancer	2.03e-05	0.000432	CcSEcCtD
Gefitinib—Fatigue—Paclitaxel—lung cancer	2.03e-05	0.000432	CcSEcCtD
Gefitinib—Hepatitis—Methotrexate—lung cancer	2.02e-05	0.00043	CcSEcCtD
Gefitinib—Haemorrhage—Methotrexate—lung cancer	2.02e-05	0.00043	CcSEcCtD
Gefitinib—Asthenia—Gemcitabine—lung cancer	2.02e-05	0.000429	CcSEcCtD
Gefitinib—Pain—Paclitaxel—lung cancer	2.01e-05	0.000428	CcSEcCtD
Gefitinib—Constipation—Paclitaxel—lung cancer	2.01e-05	0.000428	CcSEcCtD
Gefitinib—Urinary tract disorder—Methotrexate—lung cancer	2e-05	0.000425	CcSEcCtD
Gefitinib—Pruritus—Gemcitabine—lung cancer	1.99e-05	0.000423	CcSEcCtD
Gefitinib—Urethral disorder—Methotrexate—lung cancer	1.98e-05	0.000422	CcSEcCtD
Gefitinib—Infection—Docetaxel—lung cancer	1.98e-05	0.000421	CcSEcCtD
Gefitinib—Weight decreased—Doxorubicin—lung cancer	1.98e-05	0.000421	CcSEcCtD
Gefitinib—Diarrhoea—Irinotecan—lung cancer	1.97e-05	0.00042	CcSEcCtD
Gefitinib—Pneumonia—Doxorubicin—lung cancer	1.96e-05	0.000418	CcSEcCtD
Gefitinib—Gastrointestinal pain—Etoposide—lung cancer	1.96e-05	0.000417	CcSEcCtD
Gefitinib—Shock—Docetaxel—lung cancer	1.96e-05	0.000417	CcSEcCtD
Gefitinib—Nervous system disorder—Docetaxel—lung cancer	1.96e-05	0.000416	CcSEcCtD
Gefitinib—Thrombocytopenia—Docetaxel—lung cancer	1.95e-05	0.000415	CcSEcCtD
Gefitinib—Infestation NOS—Doxorubicin—lung cancer	1.95e-05	0.000415	CcSEcCtD
Gefitinib—Infestation—Doxorubicin—lung cancer	1.95e-05	0.000415	CcSEcCtD
Gefitinib—Skin disorder—Docetaxel—lung cancer	1.94e-05	0.000412	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Doxorubicin—lung cancer	1.94e-05	0.000412	CcSEcCtD
Gefitinib—Hypersensitivity—Cisplatin—lung cancer	1.93e-05	0.000411	CcSEcCtD
Gefitinib—Gastrointestinal pain—Paclitaxel—lung cancer	1.92e-05	0.000409	CcSEcCtD
Gefitinib—Diarrhoea—Gemcitabine—lung cancer	1.92e-05	0.000409	CcSEcCtD
Gefitinib—Erythema multiforme—Methotrexate—lung cancer	1.91e-05	0.000407	CcSEcCtD
Gefitinib—Urticaria—Etoposide—lung cancer	1.91e-05	0.000406	CcSEcCtD
Gefitinib—Stomatitis—Doxorubicin—lung cancer	1.9e-05	0.000405	CcSEcCtD
Gefitinib—Anorexia—Docetaxel—lung cancer	1.9e-05	0.000404	CcSEcCtD
Gefitinib—Abdominal pain—Etoposide—lung cancer	1.9e-05	0.000404	CcSEcCtD
Gefitinib—Body temperature increased—Etoposide—lung cancer	1.9e-05	0.000404	CcSEcCtD
Gefitinib—Conjunctivitis—Doxorubicin—lung cancer	1.9e-05	0.000404	CcSEcCtD
Gefitinib—Eye disorder—Methotrexate—lung cancer	1.89e-05	0.000402	CcSEcCtD
Gefitinib—Asthenia—Cisplatin—lung cancer	1.88e-05	0.0004	CcSEcCtD
Gefitinib—Cardiac disorder—Methotrexate—lung cancer	1.88e-05	0.000399	CcSEcCtD
Gefitinib—Urticaria—Paclitaxel—lung cancer	1.87e-05	0.000398	CcSEcCtD
Gefitinib—Hypotension—Docetaxel—lung cancer	1.86e-05	0.000396	CcSEcCtD
Gefitinib—Haematuria—Doxorubicin—lung cancer	1.86e-05	0.000396	CcSEcCtD
Gefitinib—Body temperature increased—Paclitaxel—lung cancer	1.86e-05	0.000396	CcSEcCtD
Gefitinib—Abdominal pain—Paclitaxel—lung cancer	1.86e-05	0.000396	CcSEcCtD
Gefitinib—Hepatobiliary disease—Doxorubicin—lung cancer	1.85e-05	0.000393	CcSEcCtD
Gefitinib—Epistaxis—Doxorubicin—lung cancer	1.84e-05	0.000392	CcSEcCtD
Gefitinib—Angiopathy—Methotrexate—lung cancer	1.84e-05	0.000391	CcSEcCtD
Gefitinib—Vomiting—Irinotecan—lung cancer	1.83e-05	0.00039	CcSEcCtD
Gefitinib—Mediastinal disorder—Methotrexate—lung cancer	1.82e-05	0.000388	CcSEcCtD
Gefitinib—Rash—Irinotecan—lung cancer	1.82e-05	0.000387	CcSEcCtD
Gefitinib—Dermatitis—Irinotecan—lung cancer	1.82e-05	0.000387	CcSEcCtD
Gefitinib—Diarrhoea—Cisplatin—lung cancer	1.79e-05	0.000381	CcSEcCtD
Gefitinib—Alopecia—Methotrexate—lung cancer	1.79e-05	0.00038	CcSEcCtD
Gefitinib—Vomiting—Gemcitabine—lung cancer	1.79e-05	0.00038	CcSEcCtD
Gefitinib—Dyspnoea—Docetaxel—lung cancer	1.78e-05	0.000378	CcSEcCtD
Gefitinib—Rash—Gemcitabine—lung cancer	1.77e-05	0.000377	CcSEcCtD
Gefitinib—Dermatitis—Gemcitabine—lung cancer	1.77e-05	0.000377	CcSEcCtD
Gefitinib—Hypersensitivity—Etoposide—lung cancer	1.77e-05	0.000376	CcSEcCtD
Gefitinib—Malnutrition—Methotrexate—lung cancer	1.76e-05	0.000375	CcSEcCtD
Gefitinib—Haemoglobin—Doxorubicin—lung cancer	1.76e-05	0.000375	CcSEcCtD
Gefitinib—Hepatitis—Doxorubicin—lung cancer	1.75e-05	0.000373	CcSEcCtD
Gefitinib—Haemorrhage—Doxorubicin—lung cancer	1.75e-05	0.000373	CcSEcCtD
Gefitinib—Decreased appetite—Docetaxel—lung cancer	1.73e-05	0.000369	CcSEcCtD
Gefitinib—Hypersensitivity—Paclitaxel—lung cancer	1.73e-05	0.000369	CcSEcCtD
Gefitinib—Urinary tract disorder—Doxorubicin—lung cancer	1.73e-05	0.000368	CcSEcCtD
Gefitinib—Oedema peripheral—Doxorubicin—lung cancer	1.73e-05	0.000367	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Docetaxel—lung cancer	1.72e-05	0.000366	CcSEcCtD
Gefitinib—Asthenia—Etoposide—lung cancer	1.72e-05	0.000366	CcSEcCtD
Gefitinib—Fatigue—Docetaxel—lung cancer	1.72e-05	0.000366	CcSEcCtD
Gefitinib—Urethral disorder—Doxorubicin—lung cancer	1.72e-05	0.000365	CcSEcCtD
Gefitinib—Nausea—Irinotecan—lung cancer	1.71e-05	0.000365	CcSEcCtD
Gefitinib—Pain—Docetaxel—lung cancer	1.71e-05	0.000363	CcSEcCtD
Gefitinib—Constipation—Docetaxel—lung cancer	1.71e-05	0.000363	CcSEcCtD
Gefitinib—Pruritus—Etoposide—lung cancer	1.7e-05	0.000361	CcSEcCtD
Gefitinib—Asthenia—Paclitaxel—lung cancer	1.69e-05	0.000359	CcSEcCtD
Gefitinib—Nausea—Gemcitabine—lung cancer	1.67e-05	0.000355	CcSEcCtD
Gefitinib—Vomiting—Cisplatin—lung cancer	1.67e-05	0.000354	CcSEcCtD
Gefitinib—Pruritus—Paclitaxel—lung cancer	1.67e-05	0.000354	CcSEcCtD
Gefitinib—Erlotinib—ALB—lung cancer	1.66e-05	0.00771	CrCbGaD
Gefitinib—Erythema multiforme—Doxorubicin—lung cancer	1.66e-05	0.000352	CcSEcCtD
Gefitinib—Rash—Cisplatin—lung cancer	1.65e-05	0.000351	CcSEcCtD
Gefitinib—Dermatitis—Cisplatin—lung cancer	1.65e-05	0.000351	CcSEcCtD
Gefitinib—Diarrhoea—Etoposide—lung cancer	1.64e-05	0.000349	CcSEcCtD
Gefitinib—Eye disorder—Doxorubicin—lung cancer	1.64e-05	0.000348	CcSEcCtD
Gefitinib—Gastrointestinal pain—Docetaxel—lung cancer	1.63e-05	0.000347	CcSEcCtD
Gefitinib—Anaemia—Methotrexate—lung cancer	1.63e-05	0.000346	CcSEcCtD
Gefitinib—Cardiac disorder—Doxorubicin—lung cancer	1.63e-05	0.000346	CcSEcCtD
Gefitinib—Diarrhoea—Paclitaxel—lung cancer	1.61e-05	0.000342	CcSEcCtD
Gefitinib—Angiopathy—Doxorubicin—lung cancer	1.59e-05	0.000338	CcSEcCtD
Gefitinib—Malaise—Methotrexate—lung cancer	1.59e-05	0.000338	CcSEcCtD
Gefitinib—Erlotinib—ABCB1—lung cancer	1.59e-05	0.00736	CrCbGaD
Gefitinib—Mediastinal disorder—Doxorubicin—lung cancer	1.58e-05	0.000336	CcSEcCtD
Gefitinib—Abdominal pain—Docetaxel—lung cancer	1.58e-05	0.000335	CcSEcCtD
Gefitinib—Body temperature increased—Docetaxel—lung cancer	1.58e-05	0.000335	CcSEcCtD
Gefitinib—Arrhythmia—Doxorubicin—lung cancer	1.57e-05	0.000333	CcSEcCtD
Gefitinib—Nausea—Cisplatin—lung cancer	1.56e-05	0.000331	CcSEcCtD
Gefitinib—Alopecia—Doxorubicin—lung cancer	1.55e-05	0.000329	CcSEcCtD
Gefitinib—Cough—Methotrexate—lung cancer	1.54e-05	0.000327	CcSEcCtD
Gefitinib—Vomiting—Etoposide—lung cancer	1.53e-05	0.000325	CcSEcCtD
Gefitinib—Malnutrition—Doxorubicin—lung cancer	1.53e-05	0.000324	CcSEcCtD
Gefitinib—Rash—Etoposide—lung cancer	1.51e-05	0.000322	CcSEcCtD
Gefitinib—Dermatitis—Etoposide—lung cancer	1.51e-05	0.000322	CcSEcCtD
Gefitinib—Vomiting—Paclitaxel—lung cancer	1.5e-05	0.000318	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	1.49e-05	0.000317	CcSEcCtD
Gefitinib—Rash—Paclitaxel—lung cancer	1.48e-05	0.000316	CcSEcCtD
Gefitinib—Dermatitis—Paclitaxel—lung cancer	1.48e-05	0.000315	CcSEcCtD
Gefitinib—Hypersensitivity—Docetaxel—lung cancer	1.47e-05	0.000313	CcSEcCtD
Gefitinib—Asthenia—Docetaxel—lung cancer	1.43e-05	0.000304	CcSEcCtD
Gefitinib—Infection—Methotrexate—lung cancer	1.43e-05	0.000304	CcSEcCtD
Gefitinib—Nausea—Etoposide—lung cancer	1.43e-05	0.000303	CcSEcCtD
Gefitinib—Pruritus—Docetaxel—lung cancer	1.41e-05	0.0003	CcSEcCtD
Gefitinib—Nervous system disorder—Methotrexate—lung cancer	1.41e-05	0.0003	CcSEcCtD
Gefitinib—Anaemia—Doxorubicin—lung cancer	1.41e-05	0.0003	CcSEcCtD
Gefitinib—Thrombocytopenia—Methotrexate—lung cancer	1.41e-05	0.000299	CcSEcCtD
Gefitinib—Nausea—Paclitaxel—lung cancer	1.4e-05	0.000297	CcSEcCtD
Gefitinib—Skin disorder—Methotrexate—lung cancer	1.4e-05	0.000297	CcSEcCtD
Gefitinib—Malaise—Doxorubicin—lung cancer	1.38e-05	0.000293	CcSEcCtD
Gefitinib—Anorexia—Methotrexate—lung cancer	1.37e-05	0.000291	CcSEcCtD
Gefitinib—Diarrhoea—Docetaxel—lung cancer	1.36e-05	0.00029	CcSEcCtD
Gefitinib—Hypotension—Methotrexate—lung cancer	1.34e-05	0.000286	CcSEcCtD
Gefitinib—Cough—Doxorubicin—lung cancer	1.33e-05	0.000283	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	1.29e-05	0.000274	CcSEcCtD
Gefitinib—Dyspnoea—Methotrexate—lung cancer	1.28e-05	0.000273	CcSEcCtD
Gefitinib—Dry mouth—Doxorubicin—lung cancer	1.27e-05	0.00027	CcSEcCtD
Gefitinib—Vomiting—Docetaxel—lung cancer	1.27e-05	0.00027	CcSEcCtD
Gefitinib—Rash—Docetaxel—lung cancer	1.26e-05	0.000268	CcSEcCtD
Gefitinib—Dermatitis—Docetaxel—lung cancer	1.26e-05	0.000267	CcSEcCtD
Gefitinib—Decreased appetite—Methotrexate—lung cancer	1.25e-05	0.000266	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Methotrexate—lung cancer	1.24e-05	0.000264	CcSEcCtD
Gefitinib—Fatigue—Methotrexate—lung cancer	1.24e-05	0.000264	CcSEcCtD
Gefitinib—Infection—Doxorubicin—lung cancer	1.24e-05	0.000263	CcSEcCtD
Gefitinib—Pain—Methotrexate—lung cancer	1.23e-05	0.000261	CcSEcCtD
Gefitinib—Shock—Doxorubicin—lung cancer	1.22e-05	0.000261	CcSEcCtD
Gefitinib—Nervous system disorder—Doxorubicin—lung cancer	1.22e-05	0.00026	CcSEcCtD
Gefitinib—Thrombocytopenia—Doxorubicin—lung cancer	1.22e-05	0.000259	CcSEcCtD
Gefitinib—Skin disorder—Doxorubicin—lung cancer	1.21e-05	0.000257	CcSEcCtD
Gefitinib—Anorexia—Doxorubicin—lung cancer	1.19e-05	0.000252	CcSEcCtD
Gefitinib—Nausea—Docetaxel—lung cancer	1.18e-05	0.000252	CcSEcCtD
Gefitinib—Gastrointestinal pain—Methotrexate—lung cancer	1.18e-05	0.00025	CcSEcCtD
Gefitinib—Hypotension—Doxorubicin—lung cancer	1.16e-05	0.000247	CcSEcCtD
Gefitinib—Urticaria—Methotrexate—lung cancer	1.14e-05	0.000243	CcSEcCtD
Gefitinib—Abdominal pain—Methotrexate—lung cancer	1.14e-05	0.000242	CcSEcCtD
Gefitinib—Body temperature increased—Methotrexate—lung cancer	1.14e-05	0.000242	CcSEcCtD
Gefitinib—Dyspnoea—Doxorubicin—lung cancer	1.11e-05	0.000236	CcSEcCtD
Gefitinib—Vandetanib—ALB—lung cancer	1.09e-05	0.00508	CrCbGaD
Gefitinib—Decreased appetite—Doxorubicin—lung cancer	1.08e-05	0.00023	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Doxorubicin—lung cancer	1.07e-05	0.000229	CcSEcCtD
Gefitinib—Fatigue—Doxorubicin—lung cancer	1.07e-05	0.000228	CcSEcCtD
Gefitinib—Constipation—Doxorubicin—lung cancer	1.06e-05	0.000226	CcSEcCtD
Gefitinib—Pain—Doxorubicin—lung cancer	1.06e-05	0.000226	CcSEcCtD
Gefitinib—Hypersensitivity—Methotrexate—lung cancer	1.06e-05	0.000225	CcSEcCtD
Gefitinib—Asthenia—Methotrexate—lung cancer	1.03e-05	0.000219	CcSEcCtD
Gefitinib—Gastrointestinal pain—Doxorubicin—lung cancer	1.02e-05	0.000217	CcSEcCtD
Gefitinib—Pruritus—Methotrexate—lung cancer	1.02e-05	0.000216	CcSEcCtD
Gefitinib—Urticaria—Doxorubicin—lung cancer	9.89e-06	0.00021	CcSEcCtD
Gefitinib—Abdominal pain—Doxorubicin—lung cancer	9.84e-06	0.000209	CcSEcCtD
Gefitinib—Body temperature increased—Doxorubicin—lung cancer	9.84e-06	0.000209	CcSEcCtD
Gefitinib—Diarrhoea—Methotrexate—lung cancer	9.84e-06	0.000209	CcSEcCtD
Gefitinib—Bosutinib—ABCB1—lung cancer	9.77e-06	0.00453	CrCbGaD
Gefitinib—Hypersensitivity—Doxorubicin—lung cancer	9.17e-06	0.000195	CcSEcCtD
Gefitinib—Vomiting—Methotrexate—lung cancer	9.14e-06	0.000194	CcSEcCtD
Gefitinib—Rash—Methotrexate—lung cancer	9.07e-06	0.000193	CcSEcCtD
Gefitinib—Dermatitis—Methotrexate—lung cancer	9.06e-06	0.000193	CcSEcCtD
Gefitinib—Asthenia—Doxorubicin—lung cancer	8.93e-06	0.00019	CcSEcCtD
Gefitinib—Pruritus—Doxorubicin—lung cancer	8.81e-06	0.000187	CcSEcCtD
Gefitinib—Nausea—Methotrexate—lung cancer	8.54e-06	0.000182	CcSEcCtD
Gefitinib—Diarrhoea—Doxorubicin—lung cancer	8.52e-06	0.000181	CcSEcCtD
Gefitinib—Vomiting—Doxorubicin—lung cancer	7.92e-06	0.000168	CcSEcCtD
Gefitinib—Rash—Doxorubicin—lung cancer	7.85e-06	0.000167	CcSEcCtD
Gefitinib—Dermatitis—Doxorubicin—lung cancer	7.84e-06	0.000167	CcSEcCtD
Gefitinib—Nausea—Doxorubicin—lung cancer	7.4e-06	0.000157	CcSEcCtD
Gefitinib—EGFR—Signaling Pathways—BRAF—lung cancer	6.1e-07	1.38e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—TYMS—lung cancer	6.09e-07	1.37e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6R—lung cancer	6.02e-07	1.36e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GSTM1—lung cancer	6.02e-07	1.36e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CREBBP—lung cancer	6.01e-07	1.36e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—lung cancer	5.96e-07	1.35e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GNG11—lung cancer	5.96e-07	1.35e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—SRC—lung cancer	5.96e-07	1.35e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—STAT3—lung cancer	5.94e-07	1.34e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—NRAS—lung cancer	5.93e-07	1.34e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—KRAS—lung cancer	5.92e-07	1.34e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTP1—lung cancer	5.88e-07	1.33e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—EP300—lung cancer	5.85e-07	1.32e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—STK11—lung cancer	5.84e-07	1.32e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—AKT1—lung cancer	5.83e-07	1.32e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—VEGFA—lung cancer	5.8e-07	1.31e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—STK11—lung cancer	5.79e-07	1.31e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—STAT3—lung cancer	5.74e-07	1.3e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAP2K1—lung cancer	5.74e-07	1.3e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTP1—lung cancer	5.74e-07	1.3e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NRAS—lung cancer	5.73e-07	1.29e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—AKT1—lung cancer	5.72e-07	1.29e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CAT—lung cancer	5.72e-07	1.29e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CYP1A1—lung cancer	5.7e-07	1.29e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CD—lung cancer	5.7e-07	1.29e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—lung cancer	5.69e-07	1.28e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—SRC—lung cancer	5.69e-07	1.28e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—APOA1—lung cancer	5.68e-07	1.28e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALDOA—lung cancer	5.68e-07	1.28e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MAPK3—lung cancer	5.67e-07	1.28e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ERCC2—lung cancer	5.66e-07	1.28e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PIK3CA—lung cancer	5.65e-07	1.27e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—KRAS—lung cancer	5.6e-07	1.27e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CAT—lung cancer	5.58e-07	1.26e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—KRAS—lung cancer	5.58e-07	1.26e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ABCB1—lung cancer	5.56e-07	1.26e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CB—lung cancer	5.55e-07	1.25e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NCOA3—lung cancer	5.51e-07	1.24e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTGS2—lung cancer	5.5e-07	1.24e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MAPK3—lung cancer	5.49e-07	1.24e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—STAT3—lung cancer	5.48e-07	1.24e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—NRAS—lung cancer	5.47e-07	1.24e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—TYMS—lung cancer	5.46e-07	1.23e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—lung cancer	5.46e-07	1.23e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PIK3CA—lung cancer	5.44e-07	1.23e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	5.44e-07	1.23e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTP1—lung cancer	5.41e-07	1.22e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTM1—lung cancer	5.4e-07	1.22e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—APOA1—lung cancer	5.37e-07	1.21e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ADCY1—lung cancer	5.36e-07	1.21e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ABCG2—lung cancer	5.36e-07	1.21e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTP1—lung cancer	5.36e-07	1.21e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MYC—lung cancer	5.34e-07	1.21e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—TYMS—lung cancer	5.33e-07	1.2e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTM1—lung cancer	5.27e-07	1.19e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—lung cancer	5.26e-07	1.19e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CAT—lung cancer	5.26e-07	1.19e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HPGDS—lung cancer	5.26e-07	1.19e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ENO2—lung cancer	5.26e-07	1.19e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MAPK3—lung cancer	5.24e-07	1.18e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PPP2R1B—lung cancer	5.22e-07	1.18e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HRAS—lung cancer	5.22e-07	1.18e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EGFR—lung cancer	5.22e-07	1.18e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CAT—lung cancer	5.22e-07	1.18e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CG—lung cancer	5.19e-07	1.17e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	5.19e-07	1.17e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—PIK3CA—lung cancer	5.15e-07	1.16e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	5.14e-07	1.16e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—PIK3CA—lung cancer	5.13e-07	1.16e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP1A1—lung cancer	5.12e-07	1.16e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ABCB1—lung cancer	5.12e-07	1.16e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MDM2—lung cancer	5.11e-07	1.15e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—KRAS—lung cancer	5.1e-07	1.15e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTT1—lung cancer	5.1e-07	1.15e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MYC—lung cancer	5.1e-07	1.15e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—RAF1—lung cancer	5.09e-07	1.15e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ERCC2—lung cancer	5.08e-07	1.15e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ABCB1—lung cancer	5.07e-07	1.15e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GCLC—lung cancer	5.04e-07	1.14e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP2A6—lung cancer	5.04e-07	1.14e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ERBB2—lung cancer	5.04e-07	1.14e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HRAS—lung cancer	5.03e-07	1.14e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—TYMS—lung cancer	5.03e-07	1.14e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL6—lung cancer	5e-07	1.13e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP1A1—lung cancer	5e-07	1.13e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—TYMS—lung cancer	4.98e-07	1.13e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—lung cancer	4.98e-07	1.12e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CB—lung cancer	4.97e-07	1.12e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MTOR—lung cancer	4.97e-07	1.12e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTM1—lung cancer	4.97e-07	1.12e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ERCC2—lung cancer	4.96e-07	1.12e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—POMC—lung cancer	4.94e-07	1.12e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KRAS—lung cancer	4.93e-07	1.11e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTM1—lung cancer	4.93e-07	1.11e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CG—lung cancer	4.9e-07	1.11e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—APOA1—lung cancer	4.89e-07	1.11e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL6—lung cancer	4.82e-07	1.09e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CREBBP—lung cancer	4.81e-07	1.09e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTEN—lung cancer	4.79e-07	1.08e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ENO1—lung cancer	4.78e-07	1.08e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCL8—lung cancer	4.78e-07	1.08e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—HRAS—lung cancer	4.76e-07	1.08e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—HRAS—lung cancer	4.74e-07	1.07e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP1A1—lung cancer	4.71e-07	1.06e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—KRAS—lung cancer	4.71e-07	1.06e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	4.69e-07	1.06e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PIK3CA—lung cancer	4.69e-07	1.06e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ERCC2—lung cancer	4.67e-07	1.05e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP1A1—lung cancer	4.67e-07	1.05e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—POMC—lung cancer	4.67e-07	1.05e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ERCC2—lung cancer	4.63e-07	1.05e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AKT1—lung cancer	4.61e-07	1.04e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—EP300—lung cancer	4.57e-07	1.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CASP3—lung cancer	4.57e-07	1.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL2—lung cancer	4.56e-07	1.03e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CD—lung cancer	4.56e-07	1.03e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CREBBP—lung cancer	4.54e-07	1.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL6—lung cancer	4.54e-07	1.03e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PIK3CA—lung cancer	4.53e-07	1.02e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ALB—lung cancer	4.5e-07	1.02e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CG—lung cancer	4.47e-07	1.01e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCND1—lung cancer	4.45e-07	1e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AKT1—lung cancer	4.45e-07	1e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—JUN—lung cancer	4.44e-07	1e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—APOA1—lung cancer	4.39e-07	9.92e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—lung cancer	4.38e-07	9.9e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HRAS—lung cancer	4.34e-07	9.79e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—PIK3CA—lung cancer	4.33e-07	9.77e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MMP9—lung cancer	4.32e-07	9.75e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CD—lung cancer	4.31e-07	9.73e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CDKN1A—lung cancer	4.3e-07	9.72e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PTEN—lung cancer	4.29e-07	9.7e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—APOA1—lung cancer	4.29e-07	9.68e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP2E1—lung cancer	4.29e-07	9.68e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ALB—lung cancer	4.25e-07	9.61e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—POMC—lung cancer	4.25e-07	9.61e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NQO1—lung cancer	4.24e-07	9.57e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	4.21e-07	9.5e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—AKT1—lung cancer	4.21e-07	9.5e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HRAS—lung cancer	4.19e-07	9.47e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AKT1—lung cancer	4.19e-07	9.46e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL6—lung cancer	4.15e-07	9.37e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CREBBP—lung cancer	4.14e-07	9.36e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—EP300—lung cancer	4.1e-07	9.25e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—APOA1—lung cancer	4.04e-07	9.13e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL6—lung cancer	4.01e-07	9.06e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CG—lung cancer	4.01e-07	9.06e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—APOA1—lung cancer	4.01e-07	9.05e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—HRAS—lung cancer	4e-07	9.04e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SRC—lung cancer	3.98e-07	8.99e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CB—lung cancer	3.98e-07	8.98e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTGS2—lung cancer	3.94e-07	8.9e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CD—lung cancer	3.93e-07	8.87e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CG—lung cancer	3.91e-07	8.84e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—lung cancer	3.88e-07	8.76e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—STAT3—lung cancer	3.84e-07	8.67e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	3.84e-07	8.66e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NRAS—lung cancer	3.83e-07	8.65e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—IL6—lung cancer	3.83e-07	8.65e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—AKT1—lung cancer	3.83e-07	8.64e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—STK11—lung cancer	3.82e-07	8.63e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—POMC—lung cancer	3.82e-07	8.62e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CB—lung cancer	3.76e-07	8.48e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—POMC—lung cancer	3.73e-07	8.42e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS2—lung cancer	3.72e-07	8.4e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CREBBP—lung cancer	3.72e-07	8.4e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AKT1—lung cancer	3.7e-07	8.36e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CG—lung cancer	3.69e-07	8.33e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAPK3—lung cancer	3.67e-07	8.29e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CG—lung cancer	3.66e-07	8.26e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CREBBP—lung cancer	3.63e-07	8.2e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MYC—lung cancer	3.57e-07	8.06e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTP1—lung cancer	3.53e-07	7.98e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—AKT1—lung cancer	3.53e-07	7.98e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CD—lung cancer	3.53e-07	7.96e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—POMC—lung cancer	3.51e-07	7.93e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—POMC—lung cancer	3.48e-07	7.86e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ALB—lung cancer	3.48e-07	7.86e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CD—lung cancer	3.44e-07	7.77e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CAT—lung cancer	3.44e-07	7.77e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTEN—lung cancer	3.44e-07	7.76e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CB—lung cancer	3.42e-07	7.73e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CREBBP—lung cancer	3.42e-07	7.72e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ALB—lung cancer	3.4e-07	7.67e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS2—lung cancer	3.39e-07	7.66e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CREBBP—lung cancer	3.39e-07	7.66e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CA—lung cancer	3.38e-07	7.64e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ABCB1—lung cancer	3.35e-07	7.56e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KRAS—lung cancer	3.3e-07	7.45e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TYMS—lung cancer	3.29e-07	7.42e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—EP300—lung cancer	3.28e-07	7.4e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTM1—lung cancer	3.25e-07	7.34e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTEN—lung cancer	3.25e-07	7.33e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CD—lung cancer	3.24e-07	7.32e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CD—lung cancer	3.22e-07	7.26e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ALB—lung cancer	3.2e-07	7.23e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ALB—lung cancer	3.17e-07	7.17e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—EP300—lung cancer	3.09e-07	6.99e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP1A1—lung cancer	3.08e-07	6.95e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CB—lung cancer	3.07e-07	6.94e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ERCC2—lung cancer	3.05e-07	6.9e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS2—lung cancer	3.05e-07	6.88e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CA—lung cancer	3.03e-07	6.84e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CB—lung cancer	3e-07	6.77e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS2—lung cancer	2.97e-07	6.71e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTEN—lung cancer	2.96e-07	6.68e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—lung cancer	2.93e-07	6.62e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CB—lung cancer	2.83e-07	6.38e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—EP300—lung cancer	2.82e-07	6.37e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HRAS—lung cancer	2.8e-07	6.33e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CB—lung cancer	2.8e-07	6.33e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS2—lung cancer	2.8e-07	6.33e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS2—lung cancer	2.78e-07	6.27e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—AKT1—lung cancer	2.76e-07	6.24e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6—lung cancer	2.68e-07	6.06e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTEN—lung cancer	2.66e-07	6e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOA1—lung cancer	2.64e-07	5.97e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTEN—lung cancer	2.59e-07	5.85e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—EP300—lung cancer	2.53e-07	5.72e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AKT1—lung cancer	2.47e-07	5.59e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—EP300—lung cancer	2.47e-07	5.58e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTEN—lung cancer	2.44e-07	5.52e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CA—lung cancer	2.42e-07	5.47e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTEN—lung cancer	2.42e-07	5.47e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CG—lung cancer	2.41e-07	5.45e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—EP300—lung cancer	2.33e-07	5.26e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—EP300—lung cancer	2.31e-07	5.22e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—POMC—lung cancer	2.3e-07	5.19e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CA—lung cancer	2.29e-07	5.17e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CREBBP—lung cancer	2.24e-07	5.05e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CD—lung cancer	2.12e-07	4.79e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALB—lung cancer	2.09e-07	4.73e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CA—lung cancer	2.09e-07	4.71e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AKT1—lung cancer	1.98e-07	4.47e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CA—lung cancer	1.87e-07	4.23e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AKT1—lung cancer	1.87e-07	4.22e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CB—lung cancer	1.85e-07	4.17e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS2—lung cancer	1.83e-07	4.14e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CA—lung cancer	1.83e-07	4.13e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CA—lung cancer	1.72e-07	3.89e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CA—lung cancer	1.71e-07	3.86e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AKT1—lung cancer	1.7e-07	3.85e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTEN—lung cancer	1.6e-07	3.61e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AKT1—lung cancer	1.53e-07	3.46e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—EP300—lung cancer	1.52e-07	3.44e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AKT1—lung cancer	1.49e-07	3.37e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AKT1—lung cancer	1.41e-07	3.18e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AKT1—lung cancer	1.4e-07	3.15e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CA—lung cancer	1.13e-07	2.54e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKT1—lung cancer	9.2e-08	2.08e-06	CbGpPWpGaD
